All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsO and PsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-06-20T09:03:21.000Z

Visual abstract | Key updates to the GRAPPA treatment recommendations for PsA

Jun 20, 2023
Share:
Learning objective: After reading this article, learners will be able to recall key updates to the GRAPPA treatment recommendations for the management of patients with PsA.

Bookmark this article

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing key updates to the GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recommendations for the treatment of psoriatic arthritis.

The original GRAPPA guidelines were published in 2009 and revised in 2015.1 These new, updated, 2021 guidelines aim to offer recommendations for the use of therapies for the six psoriatic arthritis domains (peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, and nail disease), giving guidance on treatments that can and cannot be used with associated conditions (inflammatory bowel disease and uveitis) and other comorbidities. Subcommittees were formed from GRAPPA members, with systemic literature searches completed using data published between 2013 and 2020. Treatment pathway recommendations consider the domains involved in psoriatic arthritis, patient treatment preferences, and current therapies. Additional position statements were added to address treatment with biosimilars and tapering, plus a revised research agenda.1


Visual Abstract

To download this visual abstract, click below.

Download here

  1. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479. DOI: 1038/s41584-022-00798-0

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox